As speed, cost, and global competition reshape drug development, a new class of startups — from Jeeva Clinical Trials to IntraIntel — is transforming how trials are designed, run, and connected using the power of AI and data.
Drug development has never been more promising, or more strained.
On one hand, scientific innovation is accelerating. Gene therapies, cell therapies, and precision medicines are opening entirely new possibilities, particularly for rare diseases that were once considered untreatable. On the other, the system responsible for bringing those therapies to market—clinical trials—has become one of the biggest constraints on progress.
It’s slow. It’s expensive. And increasingly, it’s out of step with the pace of science.
Bringing a new therapy to market takes an average of 10+ years and $2.6 billion per drug — and with 86% of trials failing, often due to slow data synthesis and missed signals, the system is not just slow, it is structurally broken. And for rare disease companies, where patient populations are small and geographically dispersed, the traditional model often breaks down entirely.
At the same time, the global competitive landscape is shifting.
China has rapidly accelerated its clinical development engine—streamlining trial timelines, scaling patient recruitment, and moving therapies through the pipeline faster than ever before. For U.S. and European biotech companies, speed is no longer just a business advantage. It is a strategic and regulatory necessity. The companies that will compete are those deploying compliance-native AI that accelerates trial timelines without compromising FDA or HIPAA alignment
Against that backdrop, the pressure is mounting on the entire clinical trial ecosystem to evolve. Despite the urgency, only 10.7% of pharma companies have fully implemented AI across clinical activities — leaving a first-mover window that is closing fast for platforms capable of delivering regulated, enterprise-grade results.
Regulators are beginning to adapt alongside the industry. The FDA has expanded support for decentralized clinical trials, real-world evidence, and digital health technologies. New guidance around AI, digital endpoints, and adaptive trial design is creating space for more flexible, data-driven approaches. Programs focused on rare diseases and accelerated approvals are reinforcing the need for faster, more efficient trial models—not just as a competitive advantage, but as a public health priority.
In other words, the system is being pushed—from both the top down and the bottom up—to change.
What’s emerging in response isn’t just incremental improvement. It’s a rethinking of how clinical trials are structured altogether.
A new class of startups is no longer building tools for trials. They’re beginning to build something closer to a system—one designed for speed, efficiency, and adaptability.
At the center of that shift are two companies pushing from different directions.
Jeeva Clinical Trials is rebuilding the foundation—rethinking how trials are run at the application level.
IntraIntel is approaching from above—developing an intelligence layer designed to connect, coordinate, and orchestrate everything beneath it.
Together, they point to something the industry has never fully had:
A true Clinical Trial Operating System.
The 5 Layers Defining the Shift From Tools to Systems
This story isn’t about any one company. It’s about a broader structural shift.
Clinical trials are reorganizing into a new market architecture—one that looks less like a collection of tools and more like a coordinated system. What’s emerging is a stack of interdependent layers, each solving a different part of the problem—but increasingly designed to work together.
At a high level, five layers are beginning to take shape:
Application Layer — Where Trials Are Run
This is where the core work happens: data capture, patient engagement, and study execution.
Platforms like Jeeva Clinical Trials and Curebase are rebuilding this layer from the ground up, replacing legacy systems with AI-native, patient-centric workflows.
Intelligence Layer — Where Decisions Are Made
This layer applies machine learning to optimize trial design, predict outcomes, and improve performance.
Companies like PhaseV and Trials.ai are turning what was once intuition-driven into something far more data-driven.
Recruitment & Site Layer — Where Trials Succeed or Fail
Patient enrollment and site activation remain the single biggest constraint in clinical research.
Startups like Deep 6 AI, Grove AI, and Ryght AI are using AI to identify patients, activate sites, and automate engagement.
Execution Layer — Where Trials Are Delivered
Some companies are blending software with services to rethink how trials are run.
Lindus Health is a leading example, helping sponsors execute trials end-to-end with a more efficient, tech-enabled model.
Orchestration Layer — The Missing Piece
And then there’s the newest—and most consequential—layer: the one that connects everything.
This is the newest, and most consequential, layer: the one that connects clinical, regulatory, and operational data into a single decision-ready stream, compressing 6-month trial workflows into 4-week deployments and turning compliance from a bottleneck into a built-in output. This is where IntraIntel sits.
Rather than replacing systems, orchestration platforms integrate across them — using AI agents to coordinate workflows, reconcile data, and generate outputs across the entire trial lifecycle.
It’s a an emerging category today — but within a $16 billion addressable AI-enabled clinical trial market, the orchestration layer may prove to be the highest-value real estate, sitting above every other system as the intelligence layer that makes them interoperable.
The 10 Companies Defining the Shift
Across these layers, a group of early-stage companies is beginning to define what the future of clinical trials could look like. While each is solving a different piece of the puzzle, together they begin to resemble something much larger: a coordinated system rather than a fragmented stack.
Jeeva Clinical Trials (Application Layer)
Jeeva is rebuilding the foundation of clinical research with a unified, AI-native platform that integrates data capture, patient engagement, and trial operations into a single system. Its use of AI agents to automate manual processes and enable real-time collaboration reflects a broader push toward modernizing trial infrastructure. The company has also been vocal that AI alone isn’t the breakthrough—modern infrastructure is the prerequisite.
IntraIntel (Orchestration Layer)
IntraIntel is the orchestration layer — a Software as a Medical Device (SaMD) platform that sits above existing clinical systems without requiring data migration, connecting 50+ data sources. Its platform connects clinical, regulatory, and operational data sources, using AI agents to coordinate workflows and generate outputs across the trial lifecycle. The company’s approach signals a shift from managing tools to managing the connections between them.
Curebase (Application Layer)
Curebase is part of a new wave of eClinical platforms consolidating multiple functions—EDC, eConsent, and trial operations—into a unified system. Its focus on decentralized trials and streamlined execution reflects a broader move away from fragmented vendor stacks toward integrated platforms.
Lindus Health (Execution Layer)
Lindus Health is pushing beyond software into execution, offering a model where trials are not just supported—but actively run through a combination of AI and operational infrastructure. By automating participant screening and data analysis, it reflects a shift toward outcome-driven, tech-enabled trial delivery.
Deep 6 AI (Recruitment Layer)
Deep 6 AI focuses on patient recruitment, using natural language processing to mine electronic health records and identify eligible participants faster. Its platform addresses one of the most persistent bottlenecks in clinical research.
Inato (Site & Operations Layer)
Inato is improving how sponsors identify and work with clinical trial sites, expanding access to more diverse and high-performing networks. Its approach reflects the growing importance of site intelligence in a distributed trial model.
PhaseV (Intelligence Layer)
PhaseV applies AI to optimize trial design and statistical outcomes, enabling sponsors to model and simulate studies before they begin. It represents the shift toward predictive, data-driven clinical development.
Grove AI (Recruitment + Emerging Orchestration)
Grove AI is deploying agent-based systems to automate patient engagement and recruitment workflows, acting as a digital support layer for trial operations. It offers an early look at how AI agents may become embedded in clinical workflows.
Trials.ai (Intelligence Layer)
Trials.ai focuses on improving protocol design through simulation, reducing costly amendments and increasing the likelihood of trial success. Its approach addresses inefficiencies at one of the earliest stages of development.
Ryght AI (Site Intelligence / Orchestration)
Ryght AI applies data and automation to site feasibility and selection, helping sponsors identify the right sites faster and improve trial startup timelines. It brings structure to one of the most fragmented parts of the trial process.
Where This Leads for Clinical Trials
This isn’t just a wave of new startups. It’s the early formation of a new system.
For decades, the limiting factor in clinical trials hasn’t been science—it’s been coordination. The inability to move data, decisions, and workflows seamlessly across systems has created friction at every stage. That friction is now the target.
Recent exits validate the commercial appetite for this category: Aetion was acquired for ~$400M with 40+ pharma clients; Paige was acquired by Tempus for $81M; and Icometrix was acquired by GE HealthCare — all FDA-aligned AI platforms, all commanding 6x–8x revenue multiples that reflect the premium the market places on compliant clinical AI.
What these companies are collectively building is not just better tools—but a more connected, intelligent, and coordinated way to run clinical trials. If this shift continues, the question is no longer whether clinical trials will become more automated or more data-driven.
It’s who will define the system that makes that possible.
At one end, Jeeva Clinical Trials is rebuilding the foundation—modernizing how trials are designed and executed.
At the other, IntraIntel is connecting and coordinating everything above it — turning fragmented processes into something that behaves more like a unified platform.
The Clinical Trial OS isn’t fully here yet. But for the first time, you can see its outline.
And once that system takes shape, it won’t just make trials faster.
It will change how medicine itself moves forward.
